A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 – A GLURP–MSP3 fusion protein malaria vaccine candidate

✍ Scribed by Susana Lousada-Dietrich; Prajakta S. Jogdand; Søren Jepsen; Vera V. Pinto; Sisse B. Ditlev; Michael Christiansen; Severin Olesen Larsen; Christopher B. Fox; Vanitha S. Raman; Randall F. Howard; Thomas S. Vedvick; Gregory Ireton; Darrick Carter; Steven G. Reed; Michael Theisen

• Book ID: 116963545
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 719 KB
• Volume: 29
• Category: Article
• ISSN: 0264-410X
• DOI: 10.1016/j.vaccine.2011.02.022